TY  - JOUR
A1  - Solbach, Christine
A1  - Sterner-Kock, Anja
A1  - Roller, Marc
A1  - Schnürch, Hans-Georg
A1  - Stegmüller, Manfred
A1  - Caspar-Bell, Gudrun
A1  - Schumm-Draeger, Petra-Maria
A1  - Kaufmann, Manfred
A1  - Knecht, Rainald
T1  - Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology
T2  - Neoplasia
N2  - The proliferative stimulus of the epidermal growth factor (EGF) in human epithelial cells is mediated by its binding to the external domain of the EGF receptor (EGF-R). The purpose of this study was to investigate whether growth arrest of tumors treated with anti-EGFR MAb (EMD 55900) was dependent on EGF-R expression and distinct histopathologic criteria of those neoplasms. Nine different adenocarcinomas, squamous cell carcinomas and two neoplastic epithelial cell lines (A431 and Detroit 562), which were characterized by high EGF-R expression, were xenotransplanted onto NMRI-nu/nu mice and treated with an anti-EGF-R antibody (EMD 55900). Results revealed that EGF-R expression and distinct histopathologic growth patterns play an important role for the therapeutic effect of the EGF-R antibody treatment. Tumors with high epithelial cellularity and little connective tissue responded to EMD 55900 treatment to a greater degree of growth reduction than tumors with lower cellularity. These results will be helpful for evaluation of patients who would benefit from tumor therapy with anti-EGF-R antibody.
KW  - EGFR
KW  - antibody
KW  - histology
KW  - EMD 55900
KW  - EMD 72000
Y1  - 2002
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45616
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-456163
SN  - 1476-5586
SN  - 1522-8002
N1  - User License: Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
VL  - 4
IS  - 3
SP  - 237
EP  - 242
PB  - Stockton Press
CY  - Basingstoke
ER  -